Clinical Center: Parkinson's Disease Neuroprotection Trial

临床中心：帕金森病神经保护试验

• 批准号: 7169806
• 负责人: JAY S SCHNEIDER
• 金额: $ 6.54万
• 依托单位: THOMAS JEFFERSON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2008-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7169806
• 关键词: Clinical; Center; Parkinson; Disease; Neuroprotection

DESCRIPTION (provided by applicant): The objective of this project is to perform pilot studies to identify putative neuroprotective agents for Parkinson's disease and to demonstrate convincingly in a randomized, double-blind clinical trial the efficacy of one or more pharmacological agents for slowing the progression of Parkinson's disease and to determine the toxicity and tolerability of these agents.Our Clinical Research Center will be a consortium of three local sites, each with a history and interest in conducting Parkinson's disease clinical trials. The lead site will be Thomas Jefferson University (Parkinson's Disease Research Unit), with satellite sites at Main Line Health Hospitals in Bryn Mawr, PA and Neurology Associates, P.A. in Wilmington, DE. This consortium, spanning the Philadelphia metropolitan area, the heavily populated northwestern suburbs of Philadelphia, Southeast Pennsylvania, Southern New Jersey and the entire state of Delaware will greatly enhance our ability to enroll patients in any research project in which we participate. The strength of this consortium is the collective research expertise of the participants and the resultant enhanced availability of early Parkinson's disease patients. As a result of this consortium, we are confident that we will be able to exceed the minimum number of patients to be recruited into study by approximately 50%. Each component of this Clinical Center is staffed by clinical personnel experienced in the clinical and research assessment of Parkinson's disease patients and by accomplished nurses and clinical coordinators with experience in the recruitment and retention of Parkinson's disease patients and the administration of clinical protocols.

描述（由申请人提供）：该项目的目的是进行试验研究，以确定帕金森氏病的假定神经保护剂，并在一项随机的，双盲的临床试验中令人信服地证明一种或多种药理学的功效，以减缓帕金森氏病的进展，并确定帕金森氏症的毒性和可容忍度的较慢。在进行帕金森氏病临床试验中。领先地点将是托马斯·杰斐逊大学（Thomas Jefferson University）（帕金森氏病研究部门），宾夕法尼亚州布林·莫尔（Bryn Mawr）的主线健康医院（P.A.在威尔明顿，德。这个财团跨越了费城大都市地区，人口稠密的费城西北郊区，宾夕法尼亚州东南部，新泽西州南部和整个特拉华州将极大地增强我们参与我们参加的任何研究项目的患者的能力。该财团的优势是参与者的集体研究专业知识，并提高了早期帕金森病患者的可用性。由于这个财团，我们有信心我们能够超过要招募研究的最少患者数量约50％。该临床中心的每个组成部分均由帕金森氏病患者的临床和研究评估以及有成就的护士和临床协调员进行的临床人员组成，具有招募和保留帕金森氏病患者以及临床方案的经验。